Merck Animal Health Plans $100 Million Expansion at DeSoto, Kansas, Production Campus
07/01/2020
Investments to the site include a technological expansion of the vaccine production facility, which will come on line this year, plus an additional investment of $66 million that will provide for added enhancement capabilities to be realized over the coming years.
The DeSoto site develops and manufactures a broad portfolio of vaccines for Swine, Cattle and Equine with key technologies in research and development, manufacturing and quality operations. Particularly, the site houses large-scale fermentation and cell culture, blending and filling operations and packaging, along with monoclonal antibody manufacturing for Companion Animals.
“Merck Animal Health continues to be a strong source of innovation and growth in Kansas and are a leading force in vaccine production and research in the Animal Health Corridor,” said Governor Laura Kelly. “The upgrades to these facilities will lead to more advancements in animal health and reinforce the importance of supporting biotechnology companies in the state.”
“We are excited about the opportunity to bring capital improvements, expansion in our manufacturing capacity and capabilities and advanced technology to our DeSoto facility, thereby, strengthening our footprint in the state and increasing our ability to fulfill customer demand for our portfolio of products,” said Pamela Stoops, Executive Director, DeSoto Operations, Merck Animal Health.
“Our Merck Animal Health business is making great strides in building our business for the future. That means we need to ensure our place as a leader in animal health with a substantial and sustainable U.S. facility footprint, which includes investment and expansion in our key facilities. As a leader in delivering innovative pharmaceuticals and vaccines to advance animal health and meet customer needs, this investment reflects our commitment in producing a range of animal health vaccines and pharmaceuticals for animal health diseases.”
"We continually seek new ways to improve and enhance our production and manufacturing capacity at our facilities to meet the growing needs of our animal health customers,” said Scott Bormann, Senior Vice President, North America Commercial Operations, Merck Animal Health. “Our investment in DeSoto positions us for strong long-term growth and enables us to remain a valued partner to our loyal customers through reliability and responsiveness to their needs.”
The company continues to invest in expanding its manufacturing and distribution facilities in Millsboro, Delaware; Ames, Iowa; Worthington, Minnesota; and Elkhorn and Omaha, Nebraska.”
Project Announcements
ValorFlex Packaging Plans Bowling Green, Kentucky, Production Operations
06/30/2025
Neuro.io Plans Terrebonne Parish, Louisiana, Operations
06/30/2025
Germany-Based MTU Maintenance Expands Fort Worth, Texas, MRO Operations
06/30/2025
Cascade Die Casting Group Expands High Point, North Carolina, Manufacturing Operations
06/30/2025
BuildOps Plans Raleigh, North Carolina, Operations
06/30/2025
Point Blank Enterprises Plans Wakulla County, Florida, Operations
06/30/2025
Most Read
-
20th Annual Area Development Gold and Silver Shovel Awards
Q2 2025
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and Contracting
Q2 2025
-
From Silicon to Server: Mapping the Data Center Supply Chain
Q2 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
Rethinking Life Sciences Site Selection in a Resilient and Dynamic Market
Q2 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024